192 related articles for article (PubMed ID: 35512065)
41. Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors.
Smil DV; Manku S; Chantigny YA; Leit S; Wahhab A; Yan TP; Fournel M; Maroun C; Li Z; Lemieux AM; Nicolescu A; Rahil J; Lefebvre S; Panetta A; Besterman JM; Déziel R
Bioorg Med Chem Lett; 2009 Feb; 19(3):688-92. PubMed ID: 19111466
[TBL] [Abstract][Full Text] [Related]
42. Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs).
Schäfer S; Saunders L; Eliseeva E; Velena A; Jung M; Schwienhorst A; Strasser A; Dickmanns A; Ficner R; Schlimme S; Sippl W; Verdin E; Jung M
Bioorg Med Chem; 2008 Feb; 16(4):2011-33. PubMed ID: 18054239
[TBL] [Abstract][Full Text] [Related]
43. Synthesis and biological evaluation of novel N-benzyltriazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors.
Kong SJ; Nam G; Boggu PR; Park GM; Kang JE; Park HJ; Jung YH
Bioorg Med Chem; 2023 Feb; 79():117154. PubMed ID: 36645952
[TBL] [Abstract][Full Text] [Related]
44. Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor.
Luckhurst CA; Aziz O; Beaumont V; Bürli RW; Breccia P; Maillard MC; Haughan AF; Lamers M; Leonard P; Matthews KL; Raphy G; Stott AJ; Munoz-Sanjuan I; Thomas B; Wall M; Wishart G; Yates D; Dominguez C
Bioorg Med Chem Lett; 2019 Jan; 29(1):83-88. PubMed ID: 30463802
[TBL] [Abstract][Full Text] [Related]
45. Histone deacetylase inhibitors modulate the transcriptional regulation of guanylyl cyclase/natriuretic peptide receptor-a gene: interactive roles of modified histones, histone acetyltransferase, p300, AND Sp1.
Kumar P; Tripathi S; Pandey KN
J Biol Chem; 2014 Mar; 289(10):6991-7002. PubMed ID: 24451378
[TBL] [Abstract][Full Text] [Related]
46. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.
Suzuki T; Matsuura A; Kouketsu A; Hisakawa S; Nakagawa H; Miyata N
Bioorg Med Chem; 2005 Jul; 13(13):4332-42. PubMed ID: 15927839
[TBL] [Abstract][Full Text] [Related]
47. Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases.
Brush MH; Guardiola A; Connor JH; Yao TP; Shenolikar S
J Biol Chem; 2004 Feb; 279(9):7685-91. PubMed ID: 14670976
[TBL] [Abstract][Full Text] [Related]
48. Histone deacetylase as a new target for cancer chemotherapy.
Yoshida M; Furumai R; Nishiyama M; Komatsu Y; Nishino N; Horinouchi S
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S20-6. PubMed ID: 11587361
[TBL] [Abstract][Full Text] [Related]
49. Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
Yue K; Qin M; Huang C; James Chou C; Jiang Y; Li X
Bioorg Med Chem Lett; 2022 Aug; 70():128797. PubMed ID: 35580726
[TBL] [Abstract][Full Text] [Related]
50. TRANSCRIPTIONAL ANALYSIS OF ZINC-DEPENDENT HISTONE DEACETYLASES IN SEVERAL HUMAN CANCER CELLS.
Yan L; Yefang Z; Xiaoxue C; Bin H
Exp Oncol; 2022 Aug; 44(2):126-131. PubMed ID: 35964643
[TBL] [Abstract][Full Text] [Related]
51. HDAC 3-selective inhibitor RGFP966 demonstrates anti-inflammatory properties in RAW 264.7 macrophages and mouse precision-cut lung slices by attenuating NF-κB p65 transcriptional activity.
Leus NG; van der Wouden PE; van den Bosch T; Hooghiemstra WTR; Ourailidou ME; Kistemaker LE; Bischoff R; Gosens R; Haisma HJ; Dekker FJ
Biochem Pharmacol; 2016 May; 108():58-74. PubMed ID: 26993378
[TBL] [Abstract][Full Text] [Related]
52. Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.
Lin X; Chen W; Qiu Z; Guo L; Zhu W; Li W; Wang Z; Zhang W; Zhang Z; Rong Y; Zhang M; Yu L; Zhong S; Zhao R; Wu X; Wong JC; Tang G
J Med Chem; 2015 Mar; 58(6):2809-20. PubMed ID: 25734520
[TBL] [Abstract][Full Text] [Related]
53. Discovery of novel benzimidazole derivatives as potent HDACs inhibitors against leukemia with (Thio)Hydantoin as zinc-binding moiety: Design, synthesis, enzyme inhibition, and cellular mechanistic study.
Abdulwahab HG; Mansour RE; Farghaly TA; El-Sehrawi HM
Bioorg Chem; 2024 May; 146():107284. PubMed ID: 38493640
[TBL] [Abstract][Full Text] [Related]
54. Multitarget Approach for the Treatment of Alzheimer's Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity Profiles.
Rabal O; Sánchez-Arias JA; Cuadrado-Tejedor M; de Miguel I; Pérez-González M; García-Barroso C; Ugarte A; Estella-Hermoso de Mendoza A; Sáez E; Espelosin M; Ursua S; Tan H; Wu W; Xu M; Pineda-Lucena A; Garcia-Osta A; Oyarzabal J
ACS Chem Neurosci; 2019 Sep; 10(9):4076-4101. PubMed ID: 31441641
[TBL] [Abstract][Full Text] [Related]
55. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
[TBL] [Abstract][Full Text] [Related]
56. Docking, Binding Free Energy Calculations and In Vitro Characterization of Pyrazine Linked 2-Aminobenzamides as Novel Class I Histone Deacetylase (HDAC) Inhibitors.
Bülbül EF; Melesina J; Ibrahim HS; Abdelsalam M; Vecchio A; Robaa D; Zessin M; Schutkowski M; Sippl W
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458724
[TBL] [Abstract][Full Text] [Related]
57. Fluorescent analogs of peptoid-based HDAC inhibitors: Synthesis, biological activity and cellular uptake kinetics.
Raudszus R; Nowotny R; Gertzen CGW; Schöler A; Krizsan A; Gockel I; Kalwa H; Gohlke H; Thieme R; Hansen FK
Bioorg Med Chem; 2019 Oct; 27(19):115039. PubMed ID: 31420257
[TBL] [Abstract][Full Text] [Related]
58. A novel class of anthraquinone-based HDAC6 inhibitors.
Song Y; Lim J; Seo YH
Eur J Med Chem; 2019 Feb; 164():263-272. PubMed ID: 30597327
[TBL] [Abstract][Full Text] [Related]
59. Inhibition mechanism of SAHA in HDAC: a revisit.
Zhou J; Wu R; Luo HB
Phys Chem Chem Phys; 2015 Nov; 17(44):29483-8. PubMed ID: 26497064
[TBL] [Abstract][Full Text] [Related]
60. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a new class of synthetic histone deacetylase inhibitors. 1. Design, synthesis, biological evaluation, and binding mode studies performed through three different docking procedures.
Mai A; Massa S; Ragno R; Cerbara I; Jesacher F; Loidl P; Brosch G
J Med Chem; 2003 Feb; 46(4):512-24. PubMed ID: 12570373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
